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Abstract 
 
Rationale  Electronic cigarettes are becoming increasingly popular among smokers 
worldwide.  Commonly reported reasons for use include: to quit smoking, avoid relapse,  
reduce urge to smoke, or as a perceived lower risk alternative to smoking.  Few studies 
however, have explored whether e-cigarettes deliver measurable levels of nicotine to the 
blood.    
Objective This study in experienced users explores the effect of using an 18 mg/ml nicotine 
first generation e-cigarette on blood nicotine, tobacco withdrawal symptoms and urge to 
smoke. 
Methods Fourteen regular e-cigarette users (3 female), abstinent from smoking and e-
cigarette use for 12 h, each completed a 3 h testing session.   Blood was sampled and 
questionnaires completed (tobacco-related withdrawal symptoms, urge to smoke, positive and 
negative subjective effects) at four stages: baseline, 10 puffs, 60 min of ad lib use and a 60 
min rest period.   
Results Complete sets of blood were obtained from 7 participants.  Plasma nicotine 
concentration rose significantly from a mean of 0.74 ng/ml at baseline to 6.77 ng/ml 10 min 
after 10 puffs, reaching a mean maximum of 13.91 ng/ml by the end of the ad lib puffing 
period.  Tobacco related withdrawal symptoms and urge to smoke were significantly reduced, 
direct positive effects were strongly endorsed and there was very low reporting of adverse 
effects.  
Conclusions These findings demonstrate reliable blood nicotine delivery after acute use of 
this brand/model of e-cigarette in a sample of regular users.  Future studies might usefully 
quantify nicotine delivery in relation to inhalation technique and the relationship with 
successful smoking cessation/harm reduction. 
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Introduction  
Tobacco smoking constitutes a major public health crisis causing an estimated 81,700 
deaths per year in the UK alone (NHS Information Centre, 2011), yet 21% of the population 
continue to smoke (NHS Information Centre, 2011).  Whilst nicotine is highly addictive, at 
levels commonly ingested by smokers, it is relatively non-toxic; the combustion products tar 
and carbon monoxide (CO) by contrast, are responsible for the major health risks (Royal 
College of Physicians, 2000). This recognition led to the development of nicotine 
replacement therapy (NRT) - pharmaceutical grade nicotine delivered in the form of patch, 
gum, lozenge, sub-lingual tablet, inhalator and both mouth and nasal spray used to quit 
smoking or as a longer-term less harmful alternative.  Even with the use of NRT, 93% of quit 
attempts ultimately end in failure (Etter & Stapleton, 2006) suggesting that these non-
cigarette pharmaceutical products have limitations.   
Electronic cigarettes (e-cigarettes) are battery-operated devices that deliver nicotine 
via inhaled vapour.  In the UK they are currently regulated as a consumer product under the 
General Product Safety Directive (GPSD) although the Medicines and Healthcare products 
Regulatory Agency (MHRA, 2013) recently announced plans to regulate as medicines from 
2016.  Since their introduction into the Chinese market in 2004, e-cigarettes have gained 
popularity worldwide with sales increasing year on year. E-cigarette liquid contains glycerol 
and/or propylene glycol, flavourings and nicotine (0-24 mg/mL).  This liquid  is vaporized by 
an atomizer which is activated by 'drawing' on the device or pressing a button ‘Smoking’ an 
e-cigarette therefore mimics the act of smoking and is commonly referred to as ‘vaping’   
There are over 100 different e-cigarette brands commonly divided into first and second 
generation types.  First generation e-cigarettes are simple 2-piece devices which tend to 
resemble tobacco cigarettes in size and shape.  These devices use a ‘cartomizer’ system in 
which the atomizer and e-cigarette liquid are contained within one unit (cartridge).  The 
cartridge is replaced as required and the user has no contact with the e-cigarette liquid.  
Second generation e-cigarettes are multiple piece devices which do not resemble cigarettes.  
The batteries tend to be larger, atomisers are more sophisticated, and they contain fluid filled 
cartridges (‘Tanks’) which are re-filled from bottles of e-cigarette liquid. Whilst surveys of 
users and small scale clinical studies suggest their potential for smoking cessation and harm 
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reduction (Caponneto et al., 2013; Dawkins et al., 2013; Etter & Bullen, 2011; Polosa et al., 
2011) their ability to deliver nicotine is under-explored.    
 Nicotine delivery via tobacco smoke is absorbed within 10-20 s in high concentration 
through the lungs into the bloodstream, reaching the brain in the same high concentration 
within 10 s (Royal College of Physicians, 2000).  Within 10 min of smoking, blood nicotine 
peaks at 15-30 ng/ml (Hukkanen et al., 2005; McEwen et al., 2008). Nicotine absorbed via 
commercially available NRT, by contrast, is much slower, either never reaching the peak 
achieved via tobacco smoking or taking much longer to do so depending on dose (Evans et 
al., 2006; Hukkanen et al., 2005; McEwen, West & Gaiger, 2008). Few studies have explored 
blood nicotine delivery via the e-cigarette although two early studies reported ineffective 
nicotine delivery with naïve users using first generation e-cigarettes.  Bullen et al. (2010) 
observed a peak serum nicotine level of only 1.3 ng/ml in 19.6 min and Vansickel et al. 
(2010) reported that two different brands of e-cigarettes failed to raise blood nicotine levels 
significantly over a 45 min period.   
Three subsequent lines of evidence however, indicate that naïve e-cigarette users may 
not puff effectively for nicotine delivery.  For example, e-cigarette and tobacco cigarette 
puffing characteristics differ (Trtchounian et al., 2011);  there is a learning curve to efficient 
vaping (McQueen et al., 2011); and regular users tend to use second rather than first 
generation devices  (Dawkins et al., 2013; Foulds, Veldheer & Berg, 2011).  In order to 
determine whether user experience and/or characteristics of the e-cigarette itself might 
influence blood nicotine delivery, Vansickel and Eissenberg (2013) carried out a pragmatic 
test in eight experienced e-cigarette users who used their own preferred devices and strength 
of nicotine cartridges. The brands used varied between individuals but were generally 
second-generation devices with nicotine strength e-liquid ranging from 9 to 24 mg/ml.   Mean 
plasma nicotine levels increased significantly from 2 ng/ml at baseline to 10.3 ng/ml within 5 
min, reaching a maximum concentration of 16.3 ng/ml by the end of a 60 min ad libitum 
puffing period.   
Vansickel and Eissenberg’s findings in experienced users (2013) clearly demonstrate 
that e-cigarettes can deliver measurable levels of nicotine but that this may depend on user 
technique and/or device characteristics.    The purpose of the present study was to replicate 
the Vansickel and Eissenberg (2013) study design using a more systematic approach; all 
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users were accustomed to using the e-cigarette but the device was standardized (first 
generation, 18 mg/ml nicotine cartridge) across users. The overall aim was to measure the 
acute blood nicotine delivery profile and evaluate subjective effects in regular e-cigarette 
users. 
 
Methods  
Design and ethical approval. 
A repeated measures design was used with one group of participants assessed at 7 time points 
over a 2.5 h period (Vansickel and Eissenberg, 2013).  The study was granted ethical 
approval by the University of East London Ethics Committee on 21/11/12 and was performed 
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.   
 Participants were recruited via advertisements for the study via the e-cigarette 
manufacturer’s December 2012 newsletter, Facebook page and through e-mail distribution to 
the existing customer base.  To be included in the study participants had to be: i) regular e-
cigarette users (using the device for at least 1 month and using at least one 18 mg nicotine 
cartridge per day); ii) between the ages of 18 and 55; iii) a smoker or ex-smoker; iv) 
physically fit and willing to provide blood samples; v) willing to abstain from smoking, 
vaping and the use of all nicotine-containing products for 12 h prior to testing.  Participants 
were excluded if they: i) were non-smokers; ii) were not current e-cigarette users; iii) 
reported any physical/medical condition (including asthma, diabetes, epilepsy, heart or 
neurological condition) or psychiatric condition (including depression, anxiety or psychosis); 
iv) had any history of high or low blood pressure; v) had any history of fainting or feeling 
faint associated with providing blood samples; vi) were pregnant or lactating females. All 
potential participants were given an initial telephone screening interview in order to confirm 
that they met the eligibility requirements for participation, and fully understood the nature of 
the study.  They were then sent an information sheet (via e-mail or post) and an appointment 
date.   
 A total of 14 participants (3 women) aged between 22 and 54 yrs (mean = 37) 
completed the study.  Nine described themselves as ‘White British’, one as ‘Black British’, 
two as ‘Asian’, one as ‘White Spanish’, and one as ‘Mongolian’.  Ten were educated to 
degree level or higher and four had completed GCSE/O-levels.  Six participants described 
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themselves as current smokers and eight as ex-smokers.  All were current first generation e-
cigarette  users.   
 
 
Materials 
The E-Cigarette 
The ‘SKYCIG’ is a two-piece first-generation cartomizer e-cigarette. Individually sealed 
boxed starter kits and 18 mg Crown Tobacco Bold cartridges were provided by the 
manufacturer.  E-cigarettes were fully charged prior to the assessment session.  According to 
the manufacturer’s website the cartridges contain nicotine, propylene glycol and ‘common 
natural and artificial flavourings’.   
 
 
Baseline assessment measurements 
Demographic and smoking history information was taken at baseline (age, gender, ethnicity, 
occupational status, smoking and vaping history). In order to assess baseline current or 
former dependence on tobacco the six item scale Fagerström Test of Cigarette Dependence 
(FTCD; Fagerström 2012) was employed.  Scores can range from 0 to 10 with a higher score 
indicating greater cigarette dependence.  
Tobacco related withdrawal symptoms were assessed using the Mood and Physical 
Symptoms Scale (MPSS; West & Hajek, 2004) which measures the presence and severity of 
five symptoms (depressed, irritable, restless, hungry, poor concentration) and urge to smoke. 
These were each rated ‘at this moment in time’ at 4 time points during the study.  Each 
withdrawal symptom is rated on a scale from 1 (not at all) to 5 (extremely).  Total score can 
therefore range from 5-25 with a higher score indicating a higher severity of withdrawal 
symptoms.  Urge to smoke is rated from 1 (not at all strong) to 7 (extremely strong).  
For assessing direct (positive) effects of the e-cigarette (such as ‘hit’, ‘satisfaction’, 
‘pleasant’, ‘feels like smoking’ etc.) an 11 item visual analogue scale was used based on 
Blank et al., (2008).  Participants rate each item by placing a cross through a 200 mm line 
where the far left indicates ‘not at all’ and the far right indicates ‘extremely’.  Scores are 
derived by measuring from the far left to the point of the line in mm and then halving to 
achieve a score out of 100.  A higher score therefore indicates a stronger/more positive effect.   
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Finally, in assessing (adverse) side effects of the e-cigarette we used a 21 item visual 
analogue scale based on Vansickel and Eissenberg, 2013 (confused, dizzy, headache, 
pounding heart, light-headed, nausea/feeling sick, nervous, salivation, sweaty, weak, mouth 
irritation, throat irritation, aching jaws, vomiting, flatulence/bloating, stomach ache, 
heartburn, diarrhoea, hiccups, cold hands/feet, palpitations).  As above, participants rate each 
item by placing a cross through a 200 mm line where the far left indicates ‘not at all’ and the 
far right indicates ‘extremely’.  Scores are derived as above.  A mean overall ‘side effects’ 
score is computed here by adding the scores for each item and dividing by 21.   
 
Clinical Procedure:  
Participants were asked to abstain from all tobacco/nicotine products overnight (for 12 h) 
prior to a morning testing session (Vansickel & Eissenberg, 2013).  Upon arrival at the lab, 
written informed consent was taken and participants provided an expired-air CO sample to 
verify compliance with the instruction to remain abstinent from smoking (using a calibrated 
Bedfont Micro-Smokerlyser; CO < 10 ppm required).  
 
 Baseline questionnaires (see above) were then completed before a qualified 
phlebotomy nurse inserted a venous cannula into the forearm and took a baseline 6 ml blood 
sample.  Each participant was then presented with a new boxed e-cigarette fitted with an 18 
mg crown tobacco bold flavoured cartridge and instructed to take 10 puffs (within 5 minutes, 
inter-puff interval not measured). Questionnaires were completed at 5 min, and 6 ml blood 
was collected at 10 min after the start of this 10 puff period.  This was then followed by 60 
min of ad lib puffing with 6 ml blood taken every 15 min (another 4 times).  During this time 
each participant made a note of the number of puffs taken under observation of the 
researcher.  Questionnaires were then completed again at the end of the 60 min ad lib vaping 
period which was followed by a 60 min rest period during which time participants did not use 
the e-cigarette.  A final 6 ml blood sample was then taken, and questionnaires completed at 
the end of this 60 min rest period (total of 7 blood samples taken) before the venous cannula 
was removed.  Each participant was reimbursed for his/her time and travel with £50 cash and 
a SKYCIG starter kit (retails at £49.99).   
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Blood Nicotine Analysis. 
Blood was collected in 6 ml lithium heparinised vacutainers, stored on ice and then 
centrifuged and stored at 70 
o
C prior to analysis. The bioanalysis of nicotine from plasma 
samples was conducted by Advanced Bioanalytical Service Laboratories Ltd, Welywn 
Garden City, United Kingdom. Samples were analysed by HPLC interfaced with an AB/MDS 
Sciex 4000 mass spectrometer (Digard et al, 2013). Quantification of nicotine was by peak 
area ratio. The determined lower limit of quantification for nicotine in plasma using this 
method was 0.5 ng/ml.  
 
Statistical Analysis 
Repeated measures Analysis of Variance (ANOVA) with simple contrasts to compare each 
time point to baseline was conducted for blood nicotine levels, urge to smoke and nicotine-
related withdrawal symptoms.    
Results  
Baseline tobacco smoking and vaping-related information 
 
Table 1 displays smoking and vaping-related information for the 14 participants. Baseline 
expired-air test CO levels were all < 5 ppm indicating that all participants had complied with 
the instruction to abstain from smoking. Compliance with the restriction on other nicotine use 
was retrospectively confirmed when all the measured plasma nicotine levels were < 2 ng/ml  
 
Table 1: Baseline tobacco smoking and vaping-related information 
 N Min Max Mean SD 
Age started smoking (yrs) 14 13 20 15.64 1.91 
Duration of smoking 
cessation (months)  
8 1.5 12 5.56 3.16 
Duration of SKYCIG use       
(months)  
14 1 17 4.73 3.76 
Cartridges used per day  14 1 4 1.80 0.79 
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Puffs per day  9 25 200 98.33 65.14 
FTCD  14 0 8 4.00 2.57 
CO level (ppm) 14 1 5 3.21 1.37 
Plasma nicotine (ng/ml)  14 0.5 1.41 0.69 0.31 
 
Plasma Nicotine Levels 
Complete sets of blood were obtained from seven participants, a further two were able to 
provide blood on six out of the seven occasions, one provided five samples, two provided 
four samples, one provided three and one provided two.  Reasons for failing to gain samples 
included blocked catheter lines (most commonly), a lost sample and participant requests to 
have the cannula removed. It proved difficult to obtain blood from the 3 female volunteers. 
Mean plasma nicotine level at each time point (ng/ml) are presented in Figure 1 
(based on the 7 participants for whom nicotine levels were available at every time point). 
Plasma nicotine concentration rose from a mean of 0.74 ng/ml (SEM = 0.12) at baseline to a 
mean of 6.77 ng/ml (SEM = 1.23) 10 min after 10 puffs and reached a mean maximum of 
13.91 ng/ml (SEM = 2.12) by the end of the ad lib puffing period. ANOVA revealed a 
statistically significant increase from baseline to each and every follow up time point (F1,6 
>28, p < 0.01 in all cases).  There were large individual differences in plasma nicotine levels 
(n=14).  For example, 10 min after 10 puffs, the highest level achieved was 13.4 ng/ml and 
the lowest was 2.50 ng/ml.  Similarly, after 60 min of ad lib vaping, the highest plasma 
nicotine level achieved was 25.6 ng/ml whilst the lowest was 4.35 ng/ml.  Participants took 
an average of 29 ‘puffs’ during this hour of ad lib vaping (range: 11 to 63) however, the 
correlation between number of puffs taken and plasma nicotine (ng/ml) at 60 minutes was 
only moderately and non-significantly correlated (r = 0.48, p = 0.16). 
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Figure 1: Plasma nicotine levels (ng/ml) at baseline (-5), after 10-puffs, during 60 min ad lib 
vaping, and after 60 min rest (N = 7; Error bars are ±1 SEM) 
 
 
 
Urge to Smoke and Nicotine-Related Withdrawal Symptoms  
Mean urge to smoke and nicotine-related withdrawal symptoms are displayed in Figure 2 and 
3 respectively.  There was a statistically significant reduction in urge to smoke from baseline 
to a) the end of the 10 puff period and b) the end of the 60 min ad lib vaping period (F1,12 
>12, p < 0.005 in both cases).  By the end of the 60 min rest period urge to smoke had 
increased and was no longer significantly lower than baseline (F 1,12 = 2.52, p = 0.14).  
Nicotine-related withdrawal symptoms (as measured by the MPSS) also showed a 
statistically significant reduction from baseline to both a) the end of the 10-puff period and b) 
the end of the 60 min ad lib vaping period (F1,11 > 7, p < 0.05 in both cases) but not from 
baseline to the end of the 60 min rest period (F1,11 = 4.13, p < 0.07). 
 Separate analysis of the independent items of the MPSS revealed significant 
reductions from baseline to both the end of the 10-puff period and the 60 min ad lib period 
for irritability (F1,12 > 12, p < 0.005), restlessness (F 1,12 > 8, p < 0.01) and poor concentration 
(F 1,12 > 5.5, p < 0.05) but not for depression or hunger (F 1,12 ≤ 1, ns). 
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Figure 2: Urge to smoke at baseline, at the end of the 10 puff period, at the end of the 60 min 
ad lib vaping period, and after the 60 min rest period (Error bars are ±1 SEM). 
 
 
 
Figure 3: Nicotine-related withdrawal symptoms at baseline, at the end of the 10 puff period, 
at the end of the 60 min ad lib vaping period, and after the 60 min rest period (Error bars are 
±1 SEM).  
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Direct Effects of the E-cigarette 
Mean visual analogue scale (VAS) ratings for ‘hit’ and ‘satisfaction’ after the 10 puff period 
were 74.07 (SEM = 7.15) and 70.86 (SEM = 6.28) respectively.  Responses to the items 
‘tastes like smoking’ and ‘feels like smoking’ were somewhat lower at 50.82 (SEM = 6.80) 
and 62.75 (SEM = 5.07) respectively.   
 
Adverse Effects of the e-cigarette 
Reporting of adverse side effects associated with use of the e-cigarette tested here were very 
low; total mean score was 12.81 (SEM = 1.45).  ‘Light-headedness’ showed the highest mean 
(41.36; SEM = 7.37) followed by ‘throat irritation’ (27.25; SEM =7.53).  Table 3 presents 
mean side effect scores for individual items and total score at the end of the 10-puff period 
(results were very similar, and no higher, at the end of the 60 min ad lib vaping period).    
 
 
Table 3:  Minimum, maximum, mean and SEM scores for adverse side effect of e-cigarette 
use and total score (0 = ‘not at all’, 100 = ‘extremely’) 
Side Effect Min Max Mean SEM 
Light-headedness 4 85 41.36 7.37 
Throat irritation 3.5 75.5 27.25 7.53 
Dizzy 3.5 59 24.82 5.54 
Salivation 3.5 66.5 20.71 5.58 
Mouth irritation 4.5 62 16.54 4.75 
Weak 4 69 14.86 4.90 
Cold hands/feet 3 50 10.82 3.32 
Pounding Heart 3 29 10.71 2.40 
Headache 0 56 10.61 3.81 
Sweaty 3.5 48.5 9.79 3.08 
Aching jaws 2.5 38.5 9.43 2.51 
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Nausea 2.5 35 8.39 2.29 
Nervous 2.5 30.5 7.93 2.06 
Vomiting 3.5 11 7.54 0.64 
Confused 4 12.5 7.5 0.85 
Palpitations 3 19.5 7.46 1.66 
Stomach ache 3 18 7.18 1.05 
Flatulence/Bloating 3.5 10 6.93 0.62 
Diarrhoea 3.5 11.5 6.61 0.67 
Heartburn 2.5 12 6.36 0.78 
Hiccups 3 11 6.29 0.76 
Mean TOTAL 3.9 21 12.81 1.45 
 
Discussion  
Whilst surveys and small scale clinical studies suggest successful replacement of 
smoking with e-cigarettes due to the presence of nicotine (Dawkins et al., 2013; Etter & 
Bullen, 2011; Polosa et al., 2011; Siegel, Tanwar & Wood, 2011), effects of vaping on blood 
nicotine levels are relatively unexplored.  In the current study, a significant increase in 
plasma nicotine level was observed 10 mins after taking 10 puffs on the e-cigarette (from 
0.74 ng/ml to 6.77 ng/ml).  Plasma nicotine levels continued to increase thereafter reaching a 
mean maximum of 13.91 ng/ml at the end of the 60 min ad lib puffing period.  These findings 
demonstrate that reliable plasma nicotine concentrations can be achieved via the use of a first 
generation e-cigarette among regular users.  That e-cigarettes can deliver nicotine in addition 
to providing the sensory stimulation associated with smoking, is likely to be an important 
determinant in their effectiveness for quitting or replacing smoking.   
The findings are broadly consistent with those described by Vansickel and Eissenberg 
(2013) although the slightly higher plasma nicotine concentration reported in the earlier study 
may reflect differences in devices used - second generation (Vansickel & Eissenberg) versus 
first generation (current study).  That earlier studies found minimal or no nicotine delivery 
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(Bullen et al., 2010; Vansickel et al. 2010) in naïve users is arguably due to their inexperience 
although it is also possible that the more recent positive findings reflect an improvement in 
device characteristics over the past few years.    
There was coherence in plasma nicotine kinetics for 75-80% of the users, with a 
couple of notable outliers at the lower and higher end of the range. This could reflect i) the 
inherent pharmaceutical quality of the nicotine solutions cartridges as provided in the e-
cigarete boxed sets (not chemically confirmed), ii) genetic differences in nicotine metabolism 
or iii) different inhalation techniques. A pre-cursor study could investigate aspects concerning 
quality control in advance of any further clinical study (Sanchez-Medina et al, 2007; Gao et 
al, 2008) whilst measurement of the nicotine metabolite, cotinine would enable exploration of 
individual differences in metabolism.   
In relation to inhalation technique, it is unclear whether the wide range of nicotine 
delivery is due to inefficient puffing technique in those receiving very low levels, or 
deliberate titration to receive a dose that suits the individual.   If the former is the case, such 
individuals may be prone to relapse to smoking if they are unable to receive adequate doses 
of nicotine.  In the case of the latter, if e-cigarettes do allow such titration, this may help to 
explain their appeal and the reports of successful substitution of tobacco smoking (Dawkins 
et al., 2013; Polosa et al., 2012) though it would also imply that the nicotine content may not 
be important for everyone.  Either way, assessment of e-cigarette puffing topography could 
more accurately characterise the relationship between puffing characteristics (e.g. puff 
duration, intensity and inter-puff interval) and blood nicotine delivery. If blood nicotine 
delivery does depend on a particular puffing technique, and if nicotine delivery is necessary 
for successful smoking cessation/replacement, an understanding of optimal puffing behaviour 
would be informative to both e-cigarette manufacturers and users.   
An interesting feature of the current study was the plasma nicotine levels in the 3 
female subjects. Bloods could only be collected for the first 10-30 min of the study due to 
problems with veins, but their plasma nicotine levels 10 min after the 10 puffs suggested that 
the peak plasma concentration is lower than for the male participants and that the recovery 
period could be predictably back to baseline cravings at an earlier time than men. With such 
small numbers it is not appropriate to conduct statistical tests, but the effect of gender 
certainly merits further exploration particularly given that previous studies suggest that 
nicotine content may be more important for men and sensorimotor aspects more important for 
women smokers (Dawkins et al., 2013; Perkins et al., 1999). 
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In general, the device tested here fitted with an 18 mg/ml nicotine cartridge in regular 
e-cigarette users delivers a range of blood nicotine concentrations on average comparable to 
that reported via commercially available doses of NRT (Evans et al., 2006; McEwen et al., 
2008), oral snuff (2.5g) and chewing tobacco (7.9g; Hukkanen et al, 2005). The plasma 
profiles observed here however, are a slightly different shape (less pronounced plasma max 
and more of a gradual plateau over 60 min) compared to previous profiles for NRT which 
(Choi et al., 2003; McEwen et al., 2008; Molander & Lunell, 2001; Schneider et al., 2001)..  
This is a consequence of the dose escalation design used here, rather than a single dose 
followed over time, which reflects how vapers describe using e-cigarettes in practice 
(Dawkins et al., 2013). 
The e-cigarette tested here also reduced urge to smoke and nicotine related 
withdrawal symptoms (irritability, restlessness and poor concentration) consistent with 
previous reports (Bullen et al., 2010; Dawkins et al., 2012; Vansickel & Eissenberg, 2013).  
Both urge to smoke and withdrawal symptoms increased again during the one hour rest 
period (no vaping permitted), consistent with the reduction in plasma nicotine levels during 
this period.  Levels of ‘hit’ and ‘satisfaction’ associated with using the e-cigarette were also 
fairly high, with mean scores of 74.07 and 70.86 respectively (with 100 representing the 
highest score of ‘extremely’). Consistent with the findings of two large survey studies (Etter 
& Bullen, 2011;  Dawkins et al., 2013), use of the e-cigarette was associated with very low 
reporting of side effects.  Given that these participants were regular users however, possibly 
with a vested interest in presenting e-cigarettes in a positive light, it is possible that there is 
over-reporting of positive effects and under-reporting of negative effects here.  Light-
headedness was most frequently reported which is consistent with a nicotine hit.  Similar to 
other studies (e.g. Dawkins et al., 2013), some degree of throat irritation was reported which 
may be related to the nicotine hit in the throat and/or the effects of propylene glycol which 
acts as a humectant.   
This small scale clinical laboratory study reports for the first time significantly 
elevated blood nicotine levels and positive subjective effects in regular users after using a 
standardised first generation e-cigarette.  Nevertheless, there are some limitations.  With full 
sets of blood available from only 7 participants, the sample size is small thus findings may 
not generalise to other devices or to novice users.   Females were also under-represented in 
this study and their blood was difficult to obtain so conclusions cannot be drawn in relation to 
e-cigarette nicotine delivery in women.   Finally, positive subjective effects may have been 
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over-estimated and adverse effects under-estimated in this sample of regular e-cigarette users 
who may have a vested interest in presenting the product in the most positive light.    
To conclude, the current findings demonstrate reliable nicotine delivery after acute 
administration using a first generation e-cigarette fitted with an 18 mg/ml nicotine cartridge 
in this small sample of regular users.  Urge to smoke and nicotine-related withdrawal 
symptoms were also reduced with e-cigarette use and side effects were consistent with those 
widely accepted for inhaled nicotine products.  Taken together, these findings add to the 
growing body of evidence that e-cigarettes can reliably deliver nicotine in regular users 
although there were some notable exceptions.  Further clinical studies might usefully quantify 
inhalation technique and device characteristics in relation to nicotine delivery and explore the 
relationship with successful smoking cessation.   
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